Liu 2010.

Methods	Allocation: randomised, no further details. Blindness: unclear. Duration: not reported. Design: trial with three arms. Setting: inpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS of 60 or more. N = 112. Age: not reported. Gender: not reported. History: not reported. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 10‐30 mg/day. Mean = (19.83 ± 6.50) mg/day. N = 30. 2. Risperidone: Dose range: 2‐6.5 mg/day. Mean = (3.82 ± 0.86) mg/day. N = 54. 3.Clozapine: Dose range: 150‐500 mg/day. Mean = (265.18 ± 82.59) mg/day. N = 28.
Outcomes	Global state: PANSS score decreased rate (recovery: > 75%, markedly improved: 50%‐ 5%, improved: 25%‐50%, no effect: < 25%). Adverse effects. Cost‐effect analysis. Unable to use ‐ Adverse effects: TESS total score, ECG, blood glucose and serum lipids, use of benzodiazepines and other medicine (no data).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data.
Selective reporting (reporting bias)	High risk	Data on TESS total score, ECG, blood glucose and serum lipids, use of benzodiazepines and other medicine were missing.
Other bias	Low risk	None obvious.